Q-omics provides the consensus-scored RAB41 profile across patient tissues and cancer cell-line models. RAB41 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RAB41 is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, RAB41 RNA expression shows 18,980 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, LIHC, and UVM as cancer lineages where RAB41 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB41 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB41 survival associations across molecular data types. RAB41 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB41 RNA expression–survival associations across cancer types. High RAB41 expression shows unfavorable associations in KIRC, COAD, ESCA, LIHC and KICH, but favorable associations in PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RAB41 RNA expression.
This table summarizes RAB41 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RAB41. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB41 shows lower tumor expression in THCA, LUSC, UCEC and BRCA and higher tumor expression in LIHC and HNSC. The LIHC box plot shows higher RAB41 RNA expression in tumor versus normal tissue (log2 FC = +0.550, t-test p < 0.001).
This table shows molecular features associated with RAB41 in patient tissues and cancer cell lines. In patient samples, RAB41 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB41 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
